Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.

被引：0
作者：
Felip, Enriqueta
Doger, Bernard
Majem, Margarita
Carcereny, Enric
Krebs, Matthew
Peguero, Julio Antonio
Roxburgh, Patricia
Forster, Martin
Bajaj, Pawan
Clay, Timothy Dudley
Triebel, Frederic
机构：
[1] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[2] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[3] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[4] Hosp Badalona Germans Trias & Pujol, B ARGO Grp Badalona Appl Res Grp Oncol, Catalan Inst Oncol, Med Oncol Dept, Badalona, Spain
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[7] Oncol Consultants PA, Dept Res, Houston, TX USA
[8] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[9] UCL Canc Inst, London, England
[10] Univ Coll London Hosp, London, England
[11] Griffith Univ, Brisbane, Qld, Australia
[12] St John God Hosp, Perth, WA, Australia
[13] Immutep, Res & Dev, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3100
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results
    Robert, F
    Busby, E
    Marques, MB
    Reynolds, RE
    Carey, DE
    LUNG CANCER, 2003, 42 (02) : 237 - 245
  • [32] Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Campbell, A. M.
    Cai, W. L.
    Burkhardt, D.
    Gettinger, S. N.
    Goldberg, S. B.
    Amodio, M.
    Kaech, S.
    Krishnaswamy, S.
    Decker, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S36 - S37
  • [33] Phase II study of combination of radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer: North Japan Lung Cancer Study Group 1902
    Nakagawa, Taku
    Tsukita, Yoko
    Umezawa, Rei
    Anbai, Akira
    Makiguchi, Tomonori
    Tanaka, Hisashi
    Horii, Yosuke
    Suzuki, Aya
    Morita, Ryo
    Nogawa, Hitomi
    Yokouchi, Hiroshi
    Kimura, Nozomu
    Jingu, Keiichi
    Inoue, Akira
    Sugiura, Hisatoshi
    Miyauchi, Eisaku
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group
    Karavasilis, Vasilios
    Kosmidis, Paris
    Syrigos, Konstantinos N.
    Mavropoulou, Polyxeni
    Dimopoulos, Meletios A.
    Kotoula, Vassiliki
    Pectasides, Dimitrios
    Boukovinas, Ioannis
    Klouvas, George
    Kalogera-Fountzila, Anna
    Papandreou, Christos N.
    Fountzilas, George
    Briasoulis, Evangelos
    ANTICANCER RESEARCH, 2014, 34 (10) : 5649 - 5655
  • [35] Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
    Sands, Jacob
    Ahn, Myung-Ju
    Lisberg, Aaron
    Cho, Byoung Chul
    Blumenschein, George, Jr.
    Shum, Elaine
    Pons Tostivint, Elvire
    Goto, Yasushi
    Yoh, Kiyotaka
    Heist, Rebecca
    Shimizu, Junichi
    Lee, Jong-Seok
    Baas, Paul
    Planchard, David
    Perol, Maurice
    Felip, Enriqueta
    Su, Wu-Chou
    Zebger-Gong, Hong
    Lan, Lan
    Liu, Chelsea
    Howarth, Paul
    Chiaverelli, Rachel
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (10) : 1254 - 1265
  • [36] Hyperfractionated accelerated radiotherapy (HART) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (NSCLC):: Results of a phase II study for patients ineligible for combination radiochemotherapy
    Koutaïssoff, S
    Wellmann, D
    Coucke, P
    Ozsahin, M
    Pampallona, S
    Mirimanoff, RO
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (05): : 1151 - 1156
  • [37] a non Platinum regimen for the Treatment of recurrent or Metastatic Squamous Cell Carcinoma of the Head and neck region. results From an Extended Phase II Study With Paclitaxel and Capecitabine
    Bentzen, Jens K. D.
    Kristensen, Claus Andrup
    Overgaard, Marie
    Rytter, Carsten
    Jensen, Kenneth
    Hansen, Hanne Sand
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
    Italiano, Antoine
    Cassier, Philippe A.
    Lin, Chia-Chi
    Alanko, Tuomo
    Peltola, Katriina J.
    Gazzah, Anas
    Shiah, Her-Shyong
    Calvo, Emiliano
    Cervantes, Andres
    Roda, Desamparados
    Tosi, Diego
    Gao, Bo
    Millward, Michael
    Warburton, Lydia
    Tanner, Minna
    Englert, Stefan
    Lambert, Stacie
    Parikh, Apurvasena
    Afar, Daniel E.
    Vosganian, Gregory
    Moreno, Victor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (02) : 417 - 431
  • [40] First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
    Antoine Italiano
    Philippe A. Cassier
    Chia-Chi Lin
    Tuomo Alanko
    Katriina J. Peltola
    Anas Gazzah
    Her-Shyong Shiah
    Emiliano Calvo
    Andrés Cervantes
    Desamparados Roda
    Diego Tosi
    Bo Gao
    Michael Millward
    Lydia Warburton
    Minna Tanner
    Stefan Englert
    Stacie Lambert
    Apurvasena Parikh
    Daniel E. Afar
    Gregory Vosganian
    Victor Moreno
    Cancer Immunology, Immunotherapy, 2022, 71 : 417 - 431
12345